Volume 5 Number 1 2026
Nanomaterial Interference and Blood Compatibility Gaps in ISO 10993 Testing of Biomaterial Interfaces.
Umayyah Osman 1*, Adam Shah Abdul Majid 1, Rajesh Thangarajan 2
Biosensors and Nanotheranostics 5 (1) 1-8 https://doi.org/10.25163/biosensors.5111001
Submitted: 19 October 2026 Revised: 12 December 2026 Accepted: 20 December 2026 Published: 22 December 2026
Nanostructured biomaterials now sit at the centre of many next-generation medical devices, from vascular stents and wound matrices to implant coatings and injectable carriers. Yet the very features that make them useful (an enormous surface area, tunable charge, reactive surface chemistry) also make their biological behaviour hard to predict, and the ISO 10993 series was written largely with bulk polymers and metals in mind. This review asks how well cytotoxicity testing (ISO 10993-5) and hemocompatibility testing (ISO 10993-4) hold up when applied to biomaterial–nanomaterial interfaces, reading both standards alongside EU MDR Rule 19, FDA guidance, and the nano-specific technical report ISO/TR 10993-22. Three weaknesses recur across the literature. First, colorimetric viability assays are prone to nanomaterial interference: carbon nanotubes can sequester formazan, whereas photocatalytic TiO2 reduces tetrazolium salts without cells and may inflate apparent viability by up to 14%. Second, the robust murine cell lines favoured by the standard often tolerate insults that would injure primary human cells, and stressed cultures can return metabolic signals of 100–150% that do not reflect cell number. Third, blood testing remains fragmented; protein corona formation, contact activation, platelet secretion, and complement-mediated pseudo-allergy are rarely captured together, and static incubation ignores shear, sedimentation, and air-interface artefacts. We propose a tiered framework that begins with physicochemical characterization in exposure-relevant media, pairs metabolic assays with cell-free interference controls and high-content imaging in human cells, and evaluates all five ISO 10993-4 categories under defined flow. Such an approach should make preclinical data more comparable across laboratories and, plausibly, more predictive of clinical performance.
Keywords: ISO 10993; nanomaterials; cytotoxicity; hemocompatibility; protein corona; assay interference; complement activation; microfluidic blood models; medical device regulation
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009). Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Advanced Drug Delivery Reviews, 61(6), 428–437. https://doi.org/10.1016/j.addr.2009.03.009
Allain, J. P. (2018). Multiscale interactions between blood and metallic biomaterials. In Metallic biomaterials: Processing and interface science (pp. 317–352). Elsevier.
ASTM E2524-08. (2013). Standard test method for analysis of hemolytic properties of nanoparticles. ASTM International.
ASTM F1984-99. (2013). Standard practice for testing for whole complement activation in serum by solid materials. ASTM International.
Barshtein, G., Pajic-Lijakovic, I., & Gural, A. (2018). Role of erythrocyte aggregation in blood rheology and tissue perfusion. Current Opinion in Chemical Engineering, 22, 148–154.
Berillo, D., Al-Jwaid, A., & Caplin, J. (2021). Cytotoxicity and biocompatibility of macroporous cryogels. In Nanomaterials: Biomedical applications and toxicity (pp. 15–48). Springer.
Blok, S. L. J., Engels, G. E., & van Oeveren, W. (2016). In vitro hemocompatibility testing: The importance of fresh blood. Biointerphases, 11(2), Article 029802.
Braune, S., Grunze, M., Straub, A., & Jung, F. (2013). Are there sufficient standards for the in vitro hemocompatibility testing of biomaterials? Biointerphases, 8(1), Article 33. https://doi.org/10.1186/1559-4106-8-33
Caputo, F., Clogston, J., Calzolai, L., Rösslein, M., & Prina-Mello, A. (2019). Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL: A step by step approach combining orthogonal measurements with increasing complexity. Journal of Controlled Release, 299, 31–43.
Chanan-Khan, A., Szebeni, J., Saville, S., Le, N., Baxevanis, C., Gordon, M., & Muggia, F. (2003). Complement activation by pegylated liposomal doxorubicin (Doxil®) in cancer patients: Association with hypersensitivity reactions. Annals of Oncology, 14(9), 1430–1437.
Choi, J., Reipa, V., Hitchins, V. M., Goering, P. L., & Malinauskas, R. A. (2011). Physicochemical characterization and in vitro hemolysis evaluation of silver nanoparticles. Toxicological Sciences, 123(1), 133–143. https://doi.org/10.1093/toxsci/kfr149
D’Avenio, G., Daniele, C., & Grigioni, M. (2024). Nanostructured medical devices: Regulatory perspective and current applications. Materials, 17(8), Article 1787. https://doi.org/10.3390/ma17081787
Dahlgren, C., & Karlsson, A. (1999). Respiratory burst in human neutrophils. Journal of Immunological Methods, 232(1–2), 3–14.
Deng, Z. J., Liang, M., Monteiro, M., Toth, I., & Minchin, R. F. (2011). Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nature Nanotechnology, 6(1), 39–44. https://doi.org/10.1038/nnano.2010.250
Dobrovolskaia, M. A., & McNeil, S. E. (2013). Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. Journal of Controlled Release, 172(2), 456–466.
Food and Drug Administration. (2023). Use of International Standard ISO 10993-1, “Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process”: Guidance for industry and Food and Drug Administration staff. U.S. Department of Health and Human Services.
Goldsmith, H. L., Bell, D. N., & Braovac, S. (1995). Physical and chemical effects of red cells in the shear-induced aggregation of human platelets. Biophysical Journal, 69(4), 1584–1595.
Goyal, A., Pandey, A., Marwaha, J., & Matai, J. (2025). Standardized in vitro cytotoxicity and degradation assessment of magnesium-based biomaterials in compliance with ISO 10993-5. Journal of Materials Science: Materials in Medicine, 36(1), Article 92.
Hirsch, C., Roesslein, M., Krug, H. F., & Wick, P. (2011). Nanomaterial cell interactions: Are we on the right track? Beilstein Journal of Nanotechnology, 2, 894–902.
Ilinskaya, A. N., & Dobrovolskaia, M. A. (2013). Nanoparticles and the blood coagulation system. Part II: Safety concerns. Nanomedicine, 8(5), 773–784.
International Organization for Standardization. (2009). Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity (ISO Standard No. 10993-5:2009).
International Organization for Standardization. (2010). Nanotechnologies — Methodology for the classification and categorization of nanomaterials (ISO Technical Report No. ISO/TR 11360:2010).
International Organization for Standardization. (2011). Nanotechnologies — Nanomaterial risk evaluation (ISO Technical Report No. ISO/TR 13121:2011).
International Organization for Standardization. (2017a). Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood (ISO Standard No. 10993-4:2017).
International Organization for Standardization. (2017b). Biological evaluation of medical devices — Part 22: Guidance on nanomaterials (ISO Technical Report No. ISO/TR 10993-22:2017).
International Organization for Standardization. (2018). Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process (ISO Standard No. 10993-1:2018).
International Organization for Standardization. (2025). Biological evaluation of medical devices — Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process (ISO Standard No. 10993-1:2025).
Krajewski, S., Prucek, R., Panacek, A., Avci-Adali, M., Nolte, A., Straub, A., & Wendel, H. P. (2013). Hemocompatibility evaluation of different silver nanoparticle concentrations employing a modified Chandler-loop in vitro assay on human blood. Acta Biomaterialia, 9(7), 7460–7468.
Kyriakides, T. R., Raj, A., Tseng, T. H., Xiao, H., Nguyen, P., & Hirschi, K. K. (2021). Biocompatibility of nanomaterials and their interface with host tissues. Journal of Materials Chemistry B, 9(33), 6432–6449.
Lackner, J. M., Waldhauser, W., Hartmann, P., Bruckert, F., Weidenhaupt, M., Major, R., & Sanak, M. (2012). Hemocompatibility of inorganic physical vapor deposition (PVD) coatings on thermoplastic polyurethane polymers. Journal of Functional Biomaterials, 3(2), 283–297.
Lebaudy, E., Fournel, S., Lavalle, P., Vrana, N. E., & Gribova, V. (2020). Recent advances in antiinflammatory material design. Advanced Healthcare Materials, 10(1), Article 2001373.
Long, A. T., Kenne, E., Jung, R., Fuchs, T. A., & Renné, T. (2016). Contact system revisited: An interface between inflammation, coagulation, and innate immunity. Journal of Thrombosis and Haemostasis, 14(3), 427–437.
Lupu, A. R., & Popescu, T. (2013). The noncellular reduction of MTT tetrazolium salt by TiO2 nanoparticles and its implications for cytotoxicity assay. Toxicology in Vitro, 27(5), 1445–1450.
Maitz, M. F., Sperling, C., Wongpinyochit, T., Herklotz, M., Werner, C., & Seib, F. P. (2017). Biocompatibility assessment of silk nanoparticles: Hemocompatibility and internalization by human blood cells. Nanomedicine: Nanotechnology, Biology and Medicine, 13(8), 2633–2642.
Myers, D. D., Wolf, M. F., & Anderson, J. M. (2017). From in vivo to in vitro: The medical device testing paradigm shift. ALTEX — Alternatives to Animal Experimentation, 34(4), 479–500.
Neun, B. W., & Dobrovolskaia, M. A. (2011). Method for analysis of nanoparticle hemolytic properties in vitro. In M. A. Dobrovolskaia & S. E. McNeil (Eds.), Characterization of nanoparticles intended for drug delivery (pp. 215–224). Humana Press.
Nordling, S., Nilsson, B., & Magnusson, P. U. (2014). A novel in vitro model for studying the interactions between human whole blood and endothelium. Journal of Visualized Experiments, (96), Article e52112.
Organization for Economic Cooperation and Development. (2025). Test No. 432: In vitro 3T3 NRU phototoxicity test. OECD Publishing.
Pham, T. T., Wiedemeier, S., Maenz, S., Gastrock, G., Settmacher, U., Jandt, K. D., Zanow, J., Lüdecke, C., & Bossert, J. (2016). Hemodynamic aspects of reduced platelet adhesion on bioinspired microstructured surfaces. Colloids and Surfaces B: Biointerfaces, 145, 502–509.
Podias, A., Groth, T., & Missirlis, Y. (1995). The effect of shear rate on the adhesion/activation of human platelets in flow through a closed-loop polymeric tubular system. Journal of Biomaterials Science, Polymer Edition, 6(5), 399–410.
Radomski, A., Jurasz, P., Alonso-Escolano, D., Drews, M., Morandi, M., Malinski, T., & Radomski, M. W. (2005). Nanoparticle-induced platelet aggregation and vascular thrombosis. British Journal of Pharmacology, 146(6), 882–893.
Ramakrishnan, R., & Daly, A. C. (2026). Revisiting ISO 10993-5 in vitro cytotoxicity standard tests for evaluation of extracellular matrix-based biomaterials. International Journal of Biomaterials, 2026, Article 7395612. https://doi.org/10.1155/ijbm/7395612
Ratner, B. D. (1993). The blood compatibility catastrophe. Journal of Biomedical Materials Research, 27(3), 283–287.
Ratner, B. D. (2007). The catastrophe revisited: Blood compatibility in the 21st century. Biomaterials, 28(34), 5144–5147.
Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. (2017). Official Journal of the European Union, L 117, 1–175.
Ruggeri, M. (2020). Nanotechnology-based medical devices: From critical quality attributes to regulatory preclinical assessment [Doctoral dissertation, University of Pavia].
Rundén-Pran, E., Mariussen, E., El Yamani, N., Elje, E., Longhin, E. M., & Dusinska, M. (2022). The colony forming efficiency assay for toxicity testing of nanomaterials — Modifications for higher-throughput. Frontiers in Toxicology, 4, Article 983316.
Sossah, F. (2021). Preclinical evaluation and hemocompatibility testing of micro- and nanostructured hemoglobin carrier systems [Doctoral dissertation, Charité — Universitätsmedizin Berlin].
Steller, U., Sperling, C., Hübner, J., Hanke, R., & Werner, C. (2003). Design and evaluation of novel blood incubation systems for in vitro hemocompatibility assessment of planar solid surfaces. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 66B(1), 379–390.
Szebeni, J., & Storm, G. (2015). Complement activation-related pseudoallergy: A new class of adverse reactions to nanomedicines. Journal of Controlled Release, 219, 437–444.
Teligui, L., Dalmayrac, E., Corbeau, J. J., Bouquet, E., Godon, A., Denommé, A. S., ... & Baufreton, C. (2016). Ex vivo simulation of cardiopulmonary bypass with human blood for hemocompatibility testing. Perfusion, 31(5), 376-383.
Tenzer, S., Docter, D., Rosfa, S., Wlodarski, A., Kuharev, J., Rekik, A., Knauer, S. K., Bantz, C., Nawroth, T., Bier, C., Sirirungruang, J., Mann, W. R., Treuel, L., Zellner, R., & Stauber, R. H. (2011). Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: A comprehensive quantitative proteomic analysis. ACS Nano, 5(9), 7155–7167.
Totea, G., Ionita, D., Demetrescu, I., & Mitache, M. (2014). In vitro hemocompatibility and corrosion behavior of new Zr-binary alloys in whole human blood. Open Chemistry, 12(7), 796–803.
Urbán, P., Liptrott, N. J., & Bremer, S. (2019). Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies. WIREs Nanomedicine and Nanobiotechnology, 11(2), Article e1546.
van Oeveren, W. (2013). Obstacles in haemocompatibility testing. Scientifica, 2013, Article 392584.
Van Oeveren, W., Tielliu, I. F., & De Hart, J. (2012). Comparison of modified Chandler, roller pump, and ball valve circulation models for in vitro testing in high blood flow conditions: Application in thrombogenicity testing of different materials for vascular applications. International Journal of Biomaterials, 2012, Article 673163.
Weber, M., Steinle, H., Golombek, S., Hann, L., Schlensak, C., Wendel, H. P., & Avci-Adali, M. (2018). Blood-contacting biomaterials: In vitro evaluation of the hemocompatibility. Frontiers in Bioengineering and Biotechnology, 6, Article 99.
Westein, E., de Witt, S., Lamers, M., Cosemans, J. M., & Heemskerk, J. W. (2012). Monitoring in vitro thrombus formation with novel microfluidic devices. Platelets, 23(7), 501–509.
Wittmaack, K. (2011). Excessive delivery of nanostructured matter to submersed cells caused by rapid gravitational settling. ACS Nano, 5(5), 3766–3778.
Wörle-Knirsch, J. M., Pulskamp, K., & Krug, H. F. (2006). Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Letters, 6(6), 1261–1268.
Wu, Y., Zhang, L., Wang, Q., Li, H., & Liu, Z. (2026). Infection-responsive biodegradable magnesium implant coatings. Bioactive Materials, 58, 632–649.
Zuckerman, S. T., & Kao, W. J. (2009). Nanomaterials and biocompatibility: BioMEMS and dendrimers. In M. M. de Villiers, P. Aramwit, & G. S. Kwon (Eds.), Nanotechnology in drug delivery (pp. 193–216). Springer.
Sustainable and Green Nanomaterials in Biosensing and Nanotheranostics: Life-Cycle, Toxicity, and Circular Design Perspectives
Nanoparticle-Mediated Ferroptosis Induction Combined with MRI Monitoring in Therapy-Resistant Cancers
Engineering the Lipid Nanoparticle Through Formulation Chemistry, Analytical Characterization, and Machine-Learning-Guided Optimization of mRNA Vaccine Delivery Systems